Impact of Depressive Symptoms and Their Treatment on Completing Antiviral Treatment in Patients With Chronic Hepatitis C

Liu, Stanley S.; Schneekloth, Terry D.; Talwalkar, Jayant A.; Kim, Woojin; Poterucha, John J.; Charlton, Michael; Wiesner, Russell H.; Gross, John B.

doi:10.1097/mcg.0b013e3181dc250f

Cited by 19 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Predictors for the development of depression during PR therapy in previous studies were a history of depression, low social support, history of alcohol usage, history of intravenous drug usage, history of major depression and ribavirin dosage assignment 7,15,25–28. However, we did not find any significant variables related to development of depression, probably because of small sample size and different subject characteristics.…”

Section: Discussioncontrasting

confidence: 74%

Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea

et al. 2017

View full text Add to dashboard Cite

Background/AimsThe association between depression and chronic hepatitis C virus (HCV) infection or pegylated interferon α and ribavirin therapy (PR therapy) has not been extensively studied in Korea. We aimed to clarify the prevalence of depression and its incidence during PR therapy in chronic hepatitis C (CHC) patients.MethodsIn this prospective, multicenter study, 114 CHC patients were screened for depression using two self-reported scales, the Beck Depression Inventory-I (BDI-I) and the Hospital Anxiety and Depression scale (HADS). The incidence of depression during PR therapy was evaluated in 62 patients who underwent PR therapy during the study period.ResultsThe prevalence of baseline depression was 17.5% according to the BDI-I score ≥10 criterion and 4.4% according to the HADS-D score ≥8 criterion in the 114 CHC patients, and it was significantly associated with an unmarried state. During PR therapy, depression developed in 34.6% according to the BDI-I scale and 29.5% according to the HADS-D, which negatively affected sustained virologic response (SVR).ConclusionsThe prevalence of depression in Korean CHC patients appears to be low compared to that in Western patients; however, its incidence during PR therapy (approximately 30%) was similar to that of other populations, which led to a lower SVR rate. Active screening and multidisciplinary management of depression during PR therapy is warranted.

show abstract

Section: Discussioncontrasting

confidence: 74%

Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Antidepressants are generally thought to help adherence to HCV regimens pre-transplant without change in rates of viral responsiveness. (32) We previously found (in a different population) that LTX recipients on antidepressants at the time of transplant had significantly less acute rejection compared to unmedicated depressed recipients, (10) supporting the notion that antidepressants may help prevent graft failure through several pathways.…”

Section: Discussionmentioning

confidence: 64%

Early Treatment of Depressive Symptoms and Long-Term Survival After Liver Transplantation

Rogal

Dew

Fontes

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

While depression after liver transplantation (LTX) is associated with decreased survival, the effects of treating depression remain unknown. We assessed a previously-described, prospective cohort of 167 patients transplanted for alcohol-related liver disease from 1998–2003. Depressive symptoms were measured with the Beck Depression Inventory serially throughout the first post-transplant year. Adequacy of antidepressant treatment was measured with the Antidepressant Treatment History Form. Using Cox-proportional Hazards modeling, survival times were assessed for recipients with no depression vs. depression with adequate medications vs. depression with inadequate medications. Seventy-two recipients had depressive symptoms in the first post-transplant year. Of these, 43% (n=31) received adequate pharmacotherapy and 57% (n=41) received inadequate (n=7) or no pharmacotherapy (n=34). After a median follow-up time of 9.5 years, 32% of the inadequately treated depressed group survived vs. 52% of the adequately treated group and 56% of the non-depressed group (p=0.006). Compared to the non-depressed group, those with adequately treated depression had no significant difference in survival. However, recipients with depression and inadequate pharmacotherapy had decreased survival times compared to non-depressed recipients (HR for death=2.44, 95% CI=1.45, 4.11), controlling for other known confounders. The factor most strongly linked to long-term mortality after liver transplantation in this cohort was untreated depression.

show abstract

“…Patients with a history of psychiatric illness are more likely to be excluded from HCV clinical trials [17]. Not unexpectedly, trial participants at our site had a lower rate of mental health illness.…”

Section: Discussionmentioning

confidence: 95%

Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy

Kelly

Cooper²

2013

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

Impact of Depressive Symptoms and Their Treatment on Completing Antiviral Treatment in Patients With Chronic Hepatitis C

Cited by 19 publications

References 22 publications

Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea

Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea

Early Treatment of Depressive Symptoms and Long-Term Survival After Liver Transplantation

Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy

Contact Info

Product

Resources

About